Algae 9-cis powder to improve vision in teens with retinitis pigmentosa
Part of Eyes & vision, Genetic & congenital clinical trials.
This trial tests an algae-derived powder taken by mouth to see if it can improve visual function in teenagers with retinitis pigmentosa. Because it’s early-stage, it focuses on safety and early signs of benefit to vision tests.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 12 and 18 years old
- Have retinitis pigmentosa confirmed by a standard eye test called ERG
- Sign an informed consent form (and follow study consent rules for teens)
- Do not currently smoke
- Do not take vitamin A or beta-carotene supplements
- Be able to follow study rules (no other drug studies in the last 4 weeks)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an extract from a type of algae that is rich in a special form of vitamin A. It may help improve vision for people with retinitis pigmentosa caused by certain gene mutations that affect how the eye processes vitamin A.
This trial tests a new medicine, DSP-3077, given as a single injection into one eye to see if it is safe for people with retinitis pigmentosa. It is for adults with advanced vision loss who have no other major eye diseases.
This trial tests whether the antibiotic minocycline can slow vision loss from retinitis pigmentosa. If you are between 18 and 60 and have some remaining sight, this study may help find a new treatment.
This trial tests an experimental drug called IGT001 for people with retinitis pigmentosa, a genetic eye disease that causes vision loss. The goal is to see if it is safe and can help slow or improve vision.
This trial tests whether tiny particles from stem cells, called extracellular vesicles, can help people with retinitis pigmentosa. It aims to see if these particles are safe and can improve vision.
This trial tests an eye injection called KIO-301 for people with late-stage retinitis pigmentosa (a genetic eye disease that causes vision loss). The goal is to see if it can improve vision or slow further vision loss.
Hear when a new Retinitis Pigmentosa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.